Partner Event: BIOCOM Global Life Science Partnering Conference

  • February 01, 2012
  • February 02, 2012
  • The Lodge at Torrey Pines
BIOCOM’s second Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies.  

 
Conference Speakers *As of 1/10/12
Karen Bernstein, Chairman & Editor-in-Chief, BioCentury
Martin Birkhofer, Vice President Strategic Transactions Group, Bristol-Myers Squibb
Ben Bonifant, Practice Area Leader, Campbell Alliance
Dan Burgess, CEO & Founder, Rempex Pharmaceuticals
Remi Brouard, Vice President External Innovation, Sanofi-Aventis R&D
Keith Donnermeyer, Partner, Deloitte & Touche LLP
Mark Edwards, Managing Director, Bioscience Advisors
Luke Evnin, Managing Director, MPM Capital
Jennifer Friel Goldstein, Director, Pfizer Venture Investments
George Golumbeski, Senior Vice President Business Development, Celgene Corporation
Kurt Graves, Executive Chairman, Intarcia Therapeutics, Inc.
Faheem Hasnain, President & CEO, Receptos
Natasha Hernday, VP of Corporate Development, Seattle Genetics
Paul Laikind, Chief Business Officer and Senior VP of Business Development, Sanford Burnham Research Institute 
Patrick Mahaffy, CEO & Founder, Clovis Oncology
Brian McVeigh, Vice President, WWBD Transactions Investment Management, GlaxoSmithKline Pharmaceuticals
Bob More, General Partner, Frazier Healthcare
Polly Murphy, Vice President, Worldwide Business Development, Pfizer
Mark Noguchi, Gloabl Head of Alliance Management, Roche
Roger Pomerantz, SVP and Head Worldwide Licensing, Merck
Melinda Richter, Prescience International
Tony Rosenberg, Head of Global BD & Licensing, Novartis
Jim Schaeffer, Executive Director Worldwide Licensing & External Research, Merck Research Laboratories
Laura Shawver, CEO, Cleave Biosciences
Andy Schwab, Founder and Managing Partner, 5AM Ventures
Phillipe Tinmouth, Vice President, Business Development & Alliance Management, Vertex Pharmaceuticals, Inc. 
Kurt von Emster, Managing Director, venBio LLC
Mark Wiggins, Board Member, Zogenix

Admission
$1,995.00  reg member
$2,595.00  reg non-member


© San Diego Venture Group


    

Powered by Wild Apricot Membership Software